MA56047A - Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting - Google Patents
Composés et compositions destinés au traitement d'états pathologiques associés à une activité de stingInfo
- Publication number
- MA56047A MA56047A MA056047A MA56047A MA56047A MA 56047 A MA56047 A MA 56047A MA 056047 A MA056047 A MA 056047A MA 56047 A MA56047 A MA 56047A MA 56047 A MA56047 A MA 56047A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- compounds
- treatment
- diseases associated
- sting activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962854288P | 2019-05-29 | 2019-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA56047A true MA56047A (fr) | 2022-04-06 |
Family
ID=71787083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA056047A MA56047A (fr) | 2019-05-29 | 2020-05-29 | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220227760A1 (fr) |
EP (1) | EP3976584A1 (fr) |
JP (1) | JP2022535743A (fr) |
MA (1) | MA56047A (fr) |
WO (1) | WO2020243519A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112823036A (zh) | 2018-07-03 | 2021-05-18 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
EP4134098A4 (fr) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | Méthode de cancérothérapie |
JP2023554392A (ja) * | 2020-12-16 | 2023-12-27 | アイエフエム デュー インコーポレイテッド | Sting活性に関連する状態を治療するための化合物および組成物 |
JP2023554393A (ja) * | 2020-12-16 | 2023-12-27 | アイエフエム デュー インコーポレイテッド | Sting活性に関連する状態を治療するための化合物および組成物 |
EP4267126A1 (fr) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Méthodes de traitement du cancer |
WO2022140403A1 (fr) | 2020-12-22 | 2022-06-30 | Ifm Due, Inc. | Méthodes de traitement du cancer |
WO2022140387A1 (fr) | 2020-12-22 | 2022-06-30 | Ifm Due, Inc. | Méthodes de traitement du cancer |
JP2024502755A (ja) | 2020-12-22 | 2024-01-23 | アイエフエム デュー インコーポレイテッド | がんを処置する方法 |
WO2024064358A1 (fr) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Composés et compositions pour le traitement d'affections associées à une activité de sting |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002022603A1 (fr) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Composes de pyrazole pouvant etre utilises comme inhibiteurs de la proteine kinase |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
EP1893612B1 (fr) * | 2005-06-22 | 2011-08-03 | Plexxikon, Inc. | Derives de pyrrolo [2, 3-b]pyridine utilises comme inhibiteurs de proteines kinases |
US9701631B2 (en) | 2010-12-03 | 2017-07-11 | The Trustees Of The University Of Pennsylvania | TIP60 inhibitors |
US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
EP3060056A4 (fr) | 2013-10-21 | 2017-10-18 | Drexel University | Utilisation d'agonistes de sting pour traiter une infection chronique par le virus de l'hépatite b |
EP3110818B1 (fr) * | 2014-02-28 | 2019-10-23 | The Regents of The University of Michigan | 9h-pyrimido[4,5-b]indoles et leurs analogues associés comme inhibiteurs de bromodomaine bet |
WO2016086200A1 (fr) * | 2014-11-27 | 2016-06-02 | Genentech, Inc. | Composés 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine utilisés comme inhibiteurs de cbp et/ou de ep300 |
-
2020
- 2020-05-29 JP JP2021570361A patent/JP2022535743A/ja active Pending
- 2020-05-29 US US17/610,570 patent/US20220227760A1/en active Pending
- 2020-05-29 WO PCT/US2020/035249 patent/WO2020243519A1/fr unknown
- 2020-05-29 EP EP20746384.5A patent/EP3976584A1/fr active Pending
- 2020-05-29 MA MA056047A patent/MA56047A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022535743A (ja) | 2022-08-10 |
EP3976584A1 (fr) | 2022-04-06 |
US20220227760A1 (en) | 2022-07-21 |
WO2020243519A1 (fr) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
MA53096A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting | |
MA56047A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting | |
MA44734A (fr) | Composés et compositions destinés au traitement d'états associés à une activité de nlrp | |
MA53095A (fr) | Composés et compositions pour traiter des états pathologiques associés à une activité de sting | |
MA56193A (fr) | Composés et compositions pour traiter des états associés à une activité de sting | |
MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
MA55138A (fr) | Composés et compositions pour traiter des états pathologiques associés à une activité de sting | |
DK3906066T3 (da) | Geneterapikonstruktioner til behandling af wilsons sygdom | |
MA54753A (fr) | Composés et compositions pour traiter des états pathologiques associés à une activité de sting | |
MA46018A (fr) | Activateurs d'édition du génome | |
EA202190661A1 (ru) | Агонисты фарнезоидного х-рецептора для лечения заболевания | |
MA43168A (fr) | Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques | |
ECSP21093541A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
BR112018011308A2 (pt) | anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos | |
MA51918A (fr) | Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain | |
MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
MA51524A (fr) | Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques | |
MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
SG11202011018PA (en) | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization | |
MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
SG11202011010YA (en) | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization | |
MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance |